Last updated: April 23, 2026
Who Supplies Cefdinir (CEFDINIR) and How the Supply Chain Maps to APIs, Intermediates, and Finished Dosage?
Cefdinir (CEFDINIR) supply typically spans three tiers: API and key intermediates, contract manufacturing of finished dosage forms, and finished-goods distribution. The supplier landscape changes by market (US, EU, GCC, LATAM, APAC) and by dosage strength (capsules vs oral suspension), but the underlying manufacturing roles remain consistent across procurement channels.
What are the main supplier categories for Cefdinir?
1) Cefdinir API manufacturers
- Produce cefdinir drug substance under GMP and support DMFs/EDMFs where applicable.
- Provide API in controlled specs (assay, impurities, polymorphic form when specified, residual solvents).
2) Intermediate suppliers (key upstream synthesis)
- Supply cephalosporin core intermediates and step-specific intermediates used to build cefdinir.
- Intermediate qualification and change control flow into the API manufacturer’s quality system.
3) Finished-dose manufacturers (finished products)
- Contract manufacturers formulate and package: commonly cefdinir capsules and cefdinir oral suspension.
- They source API (or API with documented chain of identity) and perform formulation, fill-finish, and packaging under local GMP.
4) Specialty distributors and tenders (region-specific)
- Handle tendered procurement, cold-chain is usually not required for cefdinir oral forms, but packaging/serialization and regional documentation are critical.
Which companies supply Cefdinir in finished products?
Cefdinir is widely sold under brand names and generics globally, with finished-product supply anchored by branded originators (in markets where held) and large generic and specialty pharma manufacturers in others. Finished products are typically sourced through:
- Market authorization holders (MAHs) and their supply agreements
- Local distributors for tenders and hospital contracts
- Global generic companies with contract packaging or their own finished-dose lines
Because cefdinir is an established antibiotic with multiple ANDA/MA pathways, finished-goods supply is typically multi-sourced rather than single-sourced per region.
Which firms are associated with Cefdinir API and upstream intermediates?
The API and intermediate supplier set for cefdinir is also multi-source, and procurement usually comes through:
- Direct API procurement from API manufacturers
- Indirect supply via contract sourcing networks
- API through the finished-dose manufacturer’s approved supplier list
Cefdinir API sourcing often reflects:
- DMF-listed manufacturing routes
- EDQM/EMA dossier alignment for EU markets
- Persistent impurity and residual solvent controls tied to the synthetic route and purification system
How do you map “suppliers” in cefdinir procurement for R&D or sourcing?
A usable supplier map for cefdinir is built from the following procurement artifacts, each of which ties a supplier to a specific role in the chain:
1) API identity and compliance trail
- Drug substance specifications: assay (typically 98%+ range in common market specs), water content, and impurity profile.
- Residual solvent limits aligned to ICH Q3C.
- Stability and retest period with storage conditions (API typically stored dry, controlled temperature/humidity).
- DMF/EDMF linkage to finished-dose regulatory filings.
2) Manufacturing controls and change management
- GMP compliance for API and intermediates.
- Change control for:
- Synthetic route parameters
- Catalyst and solvent sources
- Purification train (crystallization conditions, filtration aids)
- Polymorph and hydrate form if specified in the regulatory package
3) Finished-dose formulation and packaging capability
- Capsule and suspension lines for:
- Correct fill weight and uniformity
- Suspension reconstitution performance and shelf-life
- Container-closure system compatibility
What supplier evidence should be used (and where it is found)?
For cefdinir, the most decision-relevant supplier evidence usually comes from:
- Regulatory submissions that list API manufacturing sites (e.g., DMF/EDMF references)
- GMP inspection records for the API site and finished-dose site
- Quality agreements and Certificates of Analysis (CoAs) for routine batch release
- Stability data from the finished-dose manufacturer for the specific dosage form and strength
For business-critical sourcing, procurement teams typically require:
- Batch CoAs for multiple consecutive lots
- Analytical methods package (or reference to compendial methods plus in-house specs)
- Serialization/packaging compliance for the target country
What are the practical takeaways for selecting cefdinir suppliers?
1) Split the evaluation by tier: API supplier risk is not the same as finished-dose supply risk.
2) Lock supplier qualification to the regulatory pathway: ensure the API site matches the dossier or that the finished-dose site’s approved suppliers cover your target markets.
3) Use impurity and residual solvent profile as the gating spec: route-linked impurities are the fastest way to detect supply drift.
4) For suspensions, qualify packaging and reconstitution behavior: formulation variance shows up at the patient-facing use level even when API quality looks compliant.
Key Takeaways
- Cefdinir supply is structured across API, intermediates, finished-dose manufacturers, and regional distributors.
- Supplier qualification should anchor on regulatory linkage (DMF/EDMF references) and batch evidence (CoAs, impurity profile, residual solvent limits).
- Finished-dose supply risk depends on formulation and packaging systems, especially for oral suspension.
- The supplier roster for cefdinir is multi-sourced by design, but compliance mapping determines which sources are usable for a given market.
FAQs
1) Are cefdinir API suppliers the same as finished-dose suppliers?
No. API manufacturers supply drug substance sites; finished-dose manufacturers formulate and package capsules or suspension using that API (often from approved supplier lists).
2) What drives cefdinir supply continuity?
API synthesis consistency (impurities and solvents), GMP inspection outcomes, and finished-dose packaging capacity, particularly for suspension lines.
3) Why do cefdinir impurity profiles matter for sourcing?
Cefdinir impurity patterns are route- and process-dependent. Changes in upstream synthesis or purification can shift impurities and trigger batch rejection or regulatory nonconformance.
4) What documentation is most important when evaluating suppliers?
DMF/EDMF linkage (where relevant), GMP evidence, CoAs for multiple lots, and specification sheets for impurities and residual solvents.
5) Is oral suspension more supplier-sensitive than capsules?
Usually yes. Suspension requires tighter alignment on excipients, container-closure compatibility, reconstitution behavior, and shelf-life stability.
References
[1] European Medicines Agency (EMA). “European public assessment reports (EPARs) and related documentation for cephalosporin products.” EMA.
[2] U.S. FDA. “Drug Master File (DMF) and regulatory guidance materials.” FDA.
[3] ICH. “Q3A/Q3B/Q3C: Impurities and residual solvents guideline documents.” International Council for Harmonisation.
[4] U.S. FDA. “Guidance for industry: ANDA submissions and drug product and drug substance chemistry, manufacturing, and controls (CMC).” FDA.
